ClinicalTrials.gg
CompletedNCT01625286BEECHUpdated Jan 18, 2023Results posted

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

A Phase 1/2 interventional study of AZD5363 when combined with weekly paclitaxel. and AZD5363 when combined with weekly paclitaxel. in Advanced or Metastatic Breast Cancer and ER+ve Advanced or Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 41 sites in 11 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Enrollment
63rd of 125
148 · median 148
Started
2012
with 5 others
Phase 1/2
12 of 198
2 open now
Registered
100th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 63rd largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2012, is one of 12 in phase 1/2, and was the 100th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of different doses and schedules of AZD5363, when in combination with paclitaxel, in treatment of patients with advanced or metastatic breast cancer. Also to investigate a selected dose and schedule of AZD5363 in combination with paclitaxel vs. paclitaxel in combination with placebo in treatment of patients with estrogen receptor-positive advanced or metastatic breast cancer, including a subgroup who have the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) tumour mutation.

Read the detailed description

This is a Phase I/II multicentre, study investigating the safety, tolerability and efficacy of a twice-daily oral formulation of AZD5363 when combined with a weekly intravenous paclitaxel infusion in patients with advanced or metastatic breast cancer. Study treatment is given in 28-day cycles, comprising three weeks on-therapy followed by one week off-therapy.

The study will be conducted in two parts:

Part A. Approximately 40 patients will be recruited to this Phase I multiple ascending-dose safety run-in evaluation of each of two intermittent dosing schedules (2 days per week or 4 days per week) of AZD5363 given in combination with weekly paclitaxel. The study population is female patients, 18 years or older, with advanced or metastatic breast cancer.

The purpose of Part A is to assess the comparative safety, tolerability, pharmacokinetics and preliminary efficacy of both schedules to determine one dose and schedule of AZD5363 to take forward to study Part B in combination with weekly paclitaxel.

Part A assessments will be made in dose-escalating cohorts of 3 to 6 patients to determine a recommended dose in each of the schedules. A total of 6 patients must be evaluated at a selected dose level for it to be confirmed as the recommended dose. All dose evaluations and recommendations will be conducted by a Safety Review Committee.

Part A Patients will undergo assessments up to to withdrawal from the study or to discontinuation of study therapy.

Part B. A minimum of 100 patients will be recruited to this Phase II double-blind, placebo-controlled, stratified and randomised evaluation of two treatment regimens: AZD5363 (at a dose selected and schedule from Part A) in combination with weekly paclitaxel vs. weekly paclitaxel plus placebo. The study population is female patients with Estrogen Receptor Positive advanced or metastatic breast cancer; of which approximately 50 will have the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) mutation.

Part B patients will be stratified by PIK3CA tumour mutation status as: tumour mutation positive or tumour mutation not-detected. Under each stratum patients will be randomised to receive either paclitaxel + AZD5363 or paclitaxel + placebo.

The purpose of Part B is to assess relative efficacy of both active and placebo regimens by comparison of: progression-free survival, overall survival, tumour response, safety and tolerability in the overall ER+ve advanced or metastatic breast cancer population, and in a subgroup of these patients with the PIK3CA tumour mutation. Patient safety and therapy tolerability will be monitored by an independent Safety Review Committee throuighout the course of Part B.

Part B patients will be followed for assessment of overall survival, or to withdrawal from the study.

03

Conditions studied

  • Advanced or Metastatic Breast Cancer
  • ER+ve Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • advanced breast cancer,
  • metastatic breast cancer,
  • ER+ve breast cancer,
  • Estrogen receptor positive breast cancer,
  • PIK3CA mutated advanced or metastatic breast cancer
  • AKT inhibitor
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of .
  • Female patient.
  • Aged at least 18 years.
  • Histological or cytological confirmation of breast cancer with evidence of advanced or disease (must be ER+ve, -ve, in Part B).
  • World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and minimum of 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • abnormalities of glucose metabolism.
  • Spinal cord compression or unless asymptomatic, treated and stable (not requiring ).
  • Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including , C and .
  • Any prior exposure to agents which inhibit AKT as the primary pharmacological activity.
  • Part A: more than two prior courses of chemotherapy (including taxanes) for advanced or breast cancer.

Part B: any prior chemotherapy for advanced or metastatic breast cancer.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Part A: Intermittent schedule (2/5)

    See intervention description below.

    Drug: AZD5363 when combined with weekly paclitaxel.

  • Experimental
    Part A: Intermittent schedule (4/3)

    See intervention description below.

    Drug: AZD5363 when combined with weekly paclitaxel.

  • Active comparator
    Part B: AZD5363 combined with paclitaxel

    See intervention description below.

    Drug: AZD5363when combined with weekly paclitaxel.

  • Placebo comparator
    Part B: paclitaxel combined with placebo

    See intervention description below.

    Drug: A placebo in combination with weekly paclitaxel.

Interventions

  • DrugAZD5363 when combined with weekly paclitaxel.

    AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

  • DrugAZD5363 when combined with weekly paclitaxel.

    AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

  • DrugAZD5363when combined with weekly paclitaxel.

    Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

  • DrugA placebo in combination with weekly paclitaxel.

    Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT) Events - Part A

    An Adverse Event (AE) or laboratory abnormality considered to be related to study drug, that starts at any time during the DLT evaluation period (Cycle 1) and is dose limiting

    Time frame: During Part A DLT evaluation period (Cycle 1, up to 28 days)

  2. Progression Free Survival (PFS) - Part B

    Time from randomisation to date of objective disease progression or death (by any cause in the absence of progression). Progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \>= 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on the study, and an absolute increase of \>=5mm, or progression of non-target lesions or the appearance of new lesions.

    Time frame: From randomisation date to date of objective disease progression or death (by any cause) whichever came first, assessed every 12 wks (median total treatment duration AZD5363=325.5 days; Placebo=245 days)

Secondary outcomes

  1. Change in Tumour Size at 12 Weeks

    Percentage change from baseline to week 12 in sum of longest diameters of target lesions as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Based on patients with measurable disease who had sufficient data available to either calculate or impute a change at 12 weeks

    Time frame: RECIST tumour assessments every 12 weeks

  2. Objective Response Rate (ORR) at Week 12

    Percentage of patients who have at least one visit response of Complete Response or Partial Response prior to any evidence of progression at week 12 as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR

    Time frame: RECIST tumour assessments every 12 weeks

  3. Best Objective Response (BOR)

    Number of patients, taking their BOR, which is their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

    Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).

  4. Overall Objective Response Rate

    Percentage of patients, taking their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. Overall Response Rate (ORR) = CR + PR

    Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).

  5. Number of Subjects Without Progression Disease at Week 12 - Part A

    Percentage of patients with a 12 week visit response of CR, PR or SD (as defined by RECIST 1.1) with no evidence of previous progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

    Time frame: up to 12 weeks

  6. Duration of Response (DOR) - Part B

    Date of first documentation of response (Complete Response/Partial Response) until the date of disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.. If a subject does not progress following a response, then their DOR will use the PFS censoring time.

    Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).

  7. Durable Response Rate (DRR) - Part B

    Percentage of patients who have a Complete Response (CR) or Partial Response (PR) lasting continuously for at least 24 weeks as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: PR, \>=30% decrease in the sum of the longest diameter of target lesions; CR, disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

    Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).

  8. Overall Survival - Part B

    The interval between the date of randomisation and the date of patient death due to any cause. All Part B patients were analysed, number of deaths is presented.

    Time frame: From date of randomisation, assessed every 12 weeks, up until the time of final statistical analysis. (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).

07

Results

Posted Apr 1, 2019
Limitations and caveats
QoL, PK/PD \& efficacy response modelling were considered non-key secondary endpoints and not disclosed at this time. QoL data was limited and considered exploratory, PK/PD and modelling were not reported in CSR. Diarrhoea burden is reported with AEs

Participant flow

Participant flow — Overall Study
MilestonePart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Started1285765456
Received azd5363/placebo treatment1285765455
Did not receive azd5363/placebo trt0000001
Completed640004037
Not completed645761419
Withdrew: Adverse event0000121
Withdrew: Death001101116
Withdrew: Withdrawal by subject0101001
Withdrew: Any reason not specifically recorded0000010
Withdrew: Progressive disease6345500
Withdrew: Lost to follow-up0000001

Outcome measures

PrimaryDose-limiting Toxicity (DLT) Events - Part A

An Adverse Event (AE) or laboratory abnormality considered to be related to study drug, that starts at any time during the DLT evaluation period (Cycle 1) and is dose limiting

Time frame:
During Part A DLT evaluation period (Cycle 1, up to 28 days)
Reported as:
Number · participants
Dose-limiting Toxicity (DLT) Events - Part A
participantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Dose-limiting Toxicity (DLT) Events - Part A02002——
PrimaryProgression Free Survival (PFS) - Part B

Time from randomisation to date of objective disease progression or death (by any cause in the absence of progression). Progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \>= 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on the study, and an absolute increase of \>=5mm, or progression of non-target lesions or the appearance of new lesions.

Time frame:
From randomisation date to date of objective disease progression or death (by any cause) whichever came first, assessed every 12 wks (median total treatment duration AZD5363=325.5 days; Placebo=245 days)
Reported as:
Median · Months
Progression Free Survival (PFS) - Part B
MonthsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Progression Free Survival (PFS) - Part B—————10.9 (8.3 to 12.4)8.4 (8.2 to 10.8)
Statistical analysis
  • Part B AZD5363 vs Part B Placebo · Regression, Cox · p = 0.308 (2-sided p-value) · Hazard ratio (hr): 0.80 · 80% CI 0.60 to 1.06Cox PH model including treatment and PIK3CA status as factors/covariates
SecondaryChange in Tumour Size at 12 Weeks

Percentage change from baseline to week 12 in sum of longest diameters of target lesions as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Based on patients with measurable disease who had sufficient data available to either calculate or impute a change at 12 weeks

Time frame:
RECIST tumour assessments every 12 weeks
Reported as:
Mean · % change from baseline
Change in Tumour Size at 12 Weeks
% change from baselinePart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Change in Tumour Size at 12 Weeks-11.0 ± 33.42-15.7 ± 13.33-19.1 ± 17.73-18.3 ± 37.74-10.2 ± 24.84-34.2 ± 28.91-25.4 ± 35.87
Statistical analysis
  • Part B AZD5363 vs Part B Placebo · ANCOVA · p = 0.081 (1-sided p-value) · Mean difference (final values): -8.9 · 80% CI -17.1 to -0.8
SecondaryObjective Response Rate (ORR) at Week 12

Percentage of patients who have at least one visit response of Complete Response or Partial Response prior to any evidence of progression at week 12 as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR

Time frame:
RECIST tumour assessments every 12 weeks
Reported as:
Number · % of participants
Objective Response Rate (ORR) at Week 12
% of participantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Objective Response Rate (ORR) at Week 1241.712.50005042.9
SecondaryBest Objective Response (BOR)

Number of patients, taking their BOR, which is their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

Time frame:
From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Reported as:
Number · Participants
Best Objective Response (BOR)
ParticipantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Complete Response (CR)0000034
Partial Response (PR)021102928
Stable Disease (SD)743431414
Progression4111268
Not Evaluable (NE)1101122
SecondaryOverall Objective Response Rate

Percentage of patients, taking their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. Overall Response Rate (ORR) = CR + PR

Time frame:
From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Reported as:
Number · % of participants
Overall Objective Response Rate
% of participantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Overall Objective Response Rate0252014.3059.357.1
SecondaryNumber of Subjects Without Progression Disease at Week 12 - Part A

Percentage of patients with a 12 week visit response of CR, PR or SD (as defined by RECIST 1.1) with no evidence of previous progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

Time frame:
up to 12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Without Progression Disease at Week 12 - Part A
ParticipantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Number of Subjects Without Progression Disease at Week 12 - Part A65342——
SecondaryDuration of Response (DOR) - Part B

Date of first documentation of response (Complete Response/Partial Response) until the date of disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.. If a subject does not progress following a response, then their DOR will use the PFS censoring time.

Time frame:
From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Reported as:
Median · Months
Duration of Response (DOR) - Part B
MonthsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Duration of Response (DOR) - Part B—————8.3 (6 to 11.3)8.2 (5.6 to 10.6)
SecondaryDurable Response Rate (DRR) - Part B

Percentage of patients who have a Complete Response (CR) or Partial Response (PR) lasting continuously for at least 24 weeks as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: PR, \>=30% decrease in the sum of the longest diameter of target lesions; CR, disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.

Time frame:
From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Reported as:
Number · % of participants
Durable Response Rate (DRR) - Part B
% of participantsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Durable Response Rate (DRR) - Part B—————48.137.5
Statistical analysis
  • Part B AZD5363 vs Part B Placebo · Regression, Logistic · p = 0.139 (1-sided p-value) · Odds ratio (or): 1.53 · 80% CI 0.93 to 2.54including treatment and PIK3CA status as factors/covariates
SecondaryOverall Survival - Part B

The interval between the date of randomisation and the date of patient death due to any cause. All Part B patients were analysed, number of deaths is presented.

Time frame:
From date of randomisation, assessed every 12 weeks, up until the time of final statistical analysis. (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Reported as:
Median · months
Overall Survival - Part B
monthsPart A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
Overall Survival - Part B—————32.8 (21.3 to 32.8)NA (20.9 to NA)
Statistical analysis
  • Part B AZD5363 vs Part B Placebo · Log Rank · p = 0.482 (2-sided p-value) · Hazard ratio (hr): 0.77 · 80% CI 0.48 to 1.24Cox PH model including treatment and PIK3CA status as factors/covariates

Adverse events

Collected over Time of signature of informed consent throughout the treatment period up to and including the follow-up period (median follow-up AZD5363 16.9 months; Placebo 15.2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Schedule 1 560 mg bd0/12 (0%)3/12 (25%)12/12 (100%)
Sched 1 - AZD5363 640 mg bd0/8 (0%)3/8 (37.5%)8/8 (100%)
Sched 2 - AZD5363 360 mg bd1/5 (20%)0/5 (0%)5/5 (100%)
Sched 2 - AZD5363 400 mg bd1/7 (14.3%)1/7 (14.3%)7/7 (100%)
Part A Schedule 2 480 mg bd0/6 (0%)4/6 (66.7%)6/6 (100%)
Part B AZD536313/54 (24.1%)13/54 (24.1%)50/54 (92.6%)
Part B Placebo15/56 (26.8%)8/55 (14.5%)48/55 (87.3%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPart A Schedule 1 560 mg bdSched 1 - AZD5363 640 mg bdSched 2 - AZD5363 360 mg bdSched 2 - AZD5363 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
PyrexiaGeneral disorders0/120/80/51/71/60/540/55
Drug hypersensitivityImmune system disorders0/120/80/50/71/60/540/55
Lower respiratory tract infection bacterialInfections and infestations0/120/80/50/71/60/540/55
PneumoniaInfections and infestations0/120/80/50/71/60/540/55
Urinary tract infectionInfections and infestations0/120/80/50/71/60/540/55
Renal failureRenal and urinary disorders0/120/80/50/71/60/540/55
AnaemiaBlood and lymphatic system disorders0/120/80/51/70/60/540/55
Febrile neutropeniaBlood and lymphatic system disorders0/120/80/51/70/60/540/55
NeutropeniaBlood and lymphatic system disorders0/120/80/51/70/60/540/55
DiarrhoeaGastrointestinal disorders0/120/80/51/70/60/540/55
Most frequent other events
Showing 10 of 320
Most frequent other events
EventPart A Schedule 1 560 mg bdSched 1 - AZD5363 640 mg bdSched 2 - AZD5363 360 mg bdSched 2 - AZD5363 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B Placebo
DiarrhoeaGastrointestinal disorders0/120/85/56/76/60/540/55
DiarrhoeaGastrointestinal disorders11/127/80/50/70/60/540/55
AstheniaGeneral disorders0/120/81/56/73/60/540/55
NauseaGastrointestinal disorders0/120/83/52/75/60/540/55
DiarrhoeaGastrointestinal disorders0/120/80/50/70/641/5415/55
VomitingGastrointestinal disorders0/120/82/52/74/60/540/55
NauseaGastrointestinal disorders8/125/80/50/70/60/540/55
AstheniaGeneral disorders6/125/80/50/70/60/540/55
DizzinessNervous system disorders3/125/80/50/72/60/540/55
Upper respiratory tract infectionInfections and infestations0/120/83/50/71/60/540/55

Baseline characteristics

All patients with data who were included in the full analysis set for Part A and the intention to treat analysis set in Part B'

Age, Continuous
Age, Continuous(Years)Part A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B PlaceboTotal
Mean52.2 ± 9.9258.8 ± 12.7856.6 ± 10.2647.1 ± 9.4149.8 ± 13.1254.3 ± 10.0157.4 ± 11.3858.8 ± 11.24
Age, Customized
Age, Customized(Participants)Part A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B PlaceboTotal
<5053142191650
>=50 - <6552333242666
>=6523101111432
Sex: Female, Male
Sex: Female, Male(Participants)Part A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B PlaceboTotal
Female1285765456148
Male00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A Schedule 1 560 mg bdPart A Schedule 1 640 mg bdPart A Schedule 2 360 mg bdPart A Schedule 2 400 mg bdPart A Schedule 2 480 mg bdPart B AZD5363Part B PlaceboTotal
Asian10000121528
Black Or African American10000001
White108576241878
American Indian or Alaska Native00000151631
Other000003710
08

Study locations

41 sites
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Montreal, Quebec H4A 3T2, Canada
  • Research Site
    Quebec, G1S 4L8, Canada
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Paris Cedex 5, 75248, France
  • Research Site
    Pierre Benite CEDEX, 69310, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Chiba-shi, 260-8717, Japan
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Oita-shi, 870-0854, Japan
  • Research Site
    Osaka-shi, 540-0006, Japan
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Estado de México, 50080, Mexico
  • Research Site
    Juchitan, 7000, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Oaxaca, 68000, Mexico
  • Research Site
    Lima, 15036, Peru
  • Research Site
    Lima, L 41, Peru
  • Research Site
    Lima, LIMA 27, Peru
  • Research Site
    Miraflores, 15046, Peru
  • Research Site
    Singapore, 119228, Singapore
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Madrid, 08035, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Malaga, 29010, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Glasgow, G12 0YN, United Kingdom
  • Research Site
    Leicester, LE1 5WW, United Kingdom
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Plymouth, PL6 8DH., United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner N. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. 2019 Jun 1;30(6):945-952. doi: 10.1093/annonc/mdz085. PubMed 30860573 ↗
  • Turner NC, Alarcon E, Armstrong AC, Philco M, Lopez Chuken YA, Sablin MP, Tamura K, Gomez Villanueva A, Perez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086. PubMed 30860570 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Jan 2017, 51 months.

Results were first posted in Apr 2019, 2 years 2 months after primary completion.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 51 months is below that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2012
First posted
Jun 21, 2012
StartActual
Oct 3, 2012
Primary completionActual
Jan 28, 2017
CompletionActual
Oct 3, 2022
Results first posted
Apr 1, 2019
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01625286
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
Oct 3, 2012
Primary completion
Jan 28, 2017
Completion
Oct 3, 2022
Results posted
Apr 1, 2019
Last update
Jan 18, 2023

Study contacts

Justin Lindemann, MBChB MBA
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion